```
=> s 186826-86-8
L1            1 186826-86-8
                (186826-86-8/RN)

=> d

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   186826-86-8  REGISTRY
ED   Entered STN:  07 Mar 1997
CN   3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-
     [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride
     (1:1)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-
     (octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride,
     (4aS-cis)-
CN   3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-
     [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-,
     monohydrochloride (9CI)
OTHER NAMES:
CN   Actira
CN   Avalox
CN   Avelox
CN   BAY 12-8039
CN   Lapinix
CN   Moxifloxacin hydrochloride
CN   Octegra
FS   STEREOSEARCH
MF   C21 H24 F N3 O4 . Cl H
CI   COM
SR   CA
LC   STN Files:   ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CBNB, CHEMCATS,
       EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROUSDDR,
       PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
CRN  (151096-09-2)

Absolute stereochemistry.  Rotation (-).
```



● HCl

```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              107 REFERENCES IN FILE CA (1907 TO DATE)
```

108 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.53	2.75

FILE 'REGISTRY' ENTERED AT 10:55:57 ON 04 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 FEB 2009 HIGHEST RN 1099859-47-8
DICTIONARY FILE UPDATES: 2 FEB 2009 HIGHEST RN 1099859-47-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> STR 186826-86-8

WARNING. SINGLE ATOM FRAGMENTS NOT INCLUDED IN MODEL:
Cl
:END

L2 STRUCTURE CREATED

=> S L2 FAM FUL

FULL SEARCH INITIATED 10:56:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 135 TO ITERATE

100.0% PROCESSED 135 ITERATIONS 54 ANSWERS
SEARCH TIME: 00.00.01

L3 54 SEA FAM FUL L2

=>

=> D SCAN

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H23 D F N3 O4

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):53

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H24 F N3 O4 . C4 H4 O4

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Double bond geometry as shown.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN β-D-Glucan, (1→3)-, carboxymethyl ether, compd. with
1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-
pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid
MF C21 H24 F N3 O4 . x C2 H4 O3 . x Unspecified

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

CM 3

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 4



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, compd. with dichloromethane (1:1:?)
MF C21 H24 F N3 O4 . x C H2 Cl2 . Cl H

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, compd. with methanol, hydrate (2:2:1:1)
MF C21 H24 F N3 O4 . 1/2 C H4 O . Cl H . 1/2 H2 O

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (2Z)-2-butenedioate (9CI)
MF C21 H24 F N3 O4 . x C4 H4 O4

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Double bond geometry as shown.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, nitrate (9CI)
MF C21 H24 F N3 O4 . x H N O3

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-
MF C21 H24 F N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, ammonium salt (1:1)
MF C21 H24 F N3 O4 . H3 N

Absolute stereochemistry. Rotation (-).



● NH_3

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinoline-3-14C-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (9CI)
MF C21 H24 F N3 O4 . x Cl H

Absolute stereochemistry.



● x HCl

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-
MF C21 H24 F N3 O4

CI COM

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H12 D12 F N3 O4

Absolute stereochemistry.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H24 F N3 O4 . C4 H6 O6

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)-, compd. with 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid (1:1)
MF C22 H29 F O5 . C21 H24 F N3 O4

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, hydrate (1:1:?)
MF C21 H24 F N3 O4 . Cl H . x H2 O

Absolute stereochemistry. Rotation (-).



● HCl

● x H_2O

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, mono(α-hydroxybenzeneacetate) (9CI)
MF C21 H24 F N3 O4 . C8 H8 O3

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, ethanedioate (9CI)
MF C21 H24 F N3 O4 . x C2 H2 O4

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, sulfate (9CI)
MF C21 H24 F N3 O4 . x H2 O4 S

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 29-Nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3α,4α,8α,9β,11α,13α,14β,16β, 17Z)-, compd. with 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid (9CI)
MF C31 H48 O6 . x C21 H24 F N3 O4

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry.
Double bond geometry as shown.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrobromide (1:?)
MF C21 H24 F N3 O4 . x Br H

Absolute stereochemistry. Rotation (-).



●x HBr

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-
MF C21 H24 F N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H23 D F N3 O4

Absolute stereochemistry.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H22 D2 F N3 O4

Absolute stereochemistry.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Immunoglobulin G1, anti-(human vascular endothelial growth factor) (human-mouse monoclonal rhuMAb-VEGF γ1-chain), disulfide with human-mouse monoclonal rhuMAb-VEGF light chain, dimer, mixt. with 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid (1:1)
MF C21 H24 F N3 O4 . Unspecified
CI MXS

CM 1

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

Absolute stereochemistry. Rotation (-).



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, mixt. with 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid and 5-fluoro-2,3-dihydro-γ,γ-dimethyl-α-[[(2-methyl-5-quinolinyl)amino]methyl]-α-(trifluoromethyl)-7-benzofuranpropanol
MF C25 H26 F4 N2 O2 . C21 H24 F N3 O4 . C14 H11 Cl2 N O2
CI MXS

CM 1



CM 2

Absolute stereochemistry. Rotation (-).



CM 3



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrofluoride (1:1)
MF C21 H24 F N3 O4 . F H

Absolute stereochemistry. Rotation (-).



● HF

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN L-Aspartic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylate (9CI)
MF C21 H24 F N3 O4 . x C4 H7 N O4

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (+).



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (2R,3R)-2,3-dihydroxybutanedioate (9CI)
MF C21 H24 F N3 O4 . x C4 H6 O6

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, phosphate (9CI)
MF C21 H24 F N3 O4 . x H3 O4 P

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinoline-3-14C-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI)
MF C21 H24 F N3 O4
CI COM

Absolute stereochemistry.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, compd. with guanidine (1:1)
MF C21 H24 F N3 O4 . C H5 N3

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, hydrate (1:1:1)
MF C21 H24 F N3 O4 . Cl H . H2 O

Absolute stereochemistry. Rotation (-).



● HCl

● H_2O

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H19 D5 F N3 O4

Absolute stereochemistry.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 D24 F N3 O4

Absolute stereochemistry.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAb V2 γ1-chain), disulfide with human-mouse monoclonal rhuFAb V2 light chain, mixt. with 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid (1:1)
MF C21 H24 F N3 O4 . Unspecified
CI MXS

CM 1

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

Absolute stereochemistry. Rotation (-).



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, acetate (1:?)
MF C21 H24 F N3 O4 . x C2 H4 O2 . Cl H

CM 1

Absolute stereochemistry. Rotation (-).



● HCl

CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, octadecanoate (1:?)
MF C21 H24 F N3 O4 . x C18 H36 O2

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Butanedioic acid, hydroxy-, (2S)-, compd. with
    1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-
    pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid (9CI)
MF C21 H24 F N3 O4 . x C4 H6 O5

    CM 1

Absolute stereochemistry. Rotation (-).



    CM 2

Absolute stereochemistry. Rotation (-).



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-
    [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-,
    2-hydroxy-1,2,3-propanetricarboxylate (9CI)
MF C21 H24 F N3 O4 . x C6 H8 O7

    CM 1

Absolute stereochemistry. Rotation (-).



CM 2



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, acetate (9CI)
MF C21 H24 F N3 O4 . x C2 H4 O2

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, tetradecanoate (9CI)
MF C21 H24 F N3 O4 . x C14 H28 O2

CM 1

Absolute stereochemistry. Rotation (-).



CM 2



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, 4-methylbenzenesulfonate (9CI)
MF C21 H24 F N3 O4 . x C7 H8 O3 S

CM 1

Absolute stereochemistry. Rotation (-).



CM 2



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (1:1)
MF C21 H24 F N3 O4 . Cl H

CI COM

Absolute stereochemistry. Rotation (-).



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H21 D3 F N3 O4

Absolute stereochemistry.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H24 F N3 O4 . C20 H18 O8

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (-).



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, 5'-ester with RNA ((2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'→3')-dT) 5'-[5-[[2,6-bis(carboxyamino)-1-oxohexyl]amino]pentyl hydrogen phosphate], sodium salt (2:1:28), mixt. with 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid
MF C21 H24 F N3 O4 . Unspecified
CI MXS

CM 1

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

Absolute stereochemistry. Rotation (-).



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, compd. with nitromethane (1:1:?)
MF C21 H24 F N3 O4 . x C H3 N O2 . Cl H

CM 1

Absolute stereochemistry. Rotation (-).



● HCl

CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hexadecanoate (1:?)
MF C21 H24 F N3 O4 . x C16 H32 O2

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

$HO_2C-(CH_2)_{14}-Me$

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (2E)-2-butenedioate (9CI)
MF C21 H24 F N3 O4 . x C4 H4 O4

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Double bond geometry as shown.



L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, 2-hydroxypropanoate (9CI)
MF C21 H24 F N3 O4 . x C3 H6 O3

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-
MF C21 H24 F N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-
MF C21 H24 F N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, methanesulfonate (9CI)
MF C21 H24 F N3 O4 . x C H4 O3 S

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

L3 54 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, trans- (9CI)
MF C21 H24 F N3 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> s l3 and ( C21 H24 F N3 O4 . Cl H . H2 O/mf or  C21 H24 F N3 O4 . x C2 H4 O2 .
Cl H/mf or  C21 H24 F N3 O4 . x C2 H4 O2/mf or  C21 H24 F N3 O4 . x C H3 N O2 . Cl
H/mf)
             1 C21 H24 F N3 O4 . CL H . H2 O/MF
             1 C21 H24 F N3 O4 . X C2 H4 O2 . CL H/MF
             1 C21 H24 F N3 O4 . X C2 H4 O2/MF
             1 C21 H24 F N3 O4 . X C H3 N O2 . CL H/MF
L4           4 L3 AND ( C21 H24 F N3 O4 . CL H . H2 O/MF OR  C21 H24 F N3 O4 .
               X C2 H4 O2 . CL H/MF OR  C21 H24 F N3 O4 . X C2 H4 O2/MF OR
               C21 H24 F N3 O4 . X C H3 N O2 . CL H/MF)

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    99.53     102.28

FILE 'CAPLUS' ENTERED AT 11:02:17 ON 04 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```


FILE COVERS 1907 - 4 Feb 2009 VOL 150 ISS 6
FILE LAST UPDATED: 3 Feb 2009 (20090203/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l4
L5          12 L4

=> d bib hitstr 12

L5   ANSWER 12 OF 12  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   1997:515377  CAPLUS
DN   127:140545
OREF 127:27017a,27020a
TI   Pharmaceuticals containing 1-Cyclopropyl-7-[(S,S)-2,8-
     diazabicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-
     cholinecarboxylic acid hydrochloride
IN   Grunenberg, Alfons; Bosche, Patrick
PA   Bayer A.-G., Germany
SO   Ger. Offen., 17 pp.
     CODEN: GWXXBX
DT   Patent
LA   German
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   DE 19546249         A1     19970619    DE 1995-19546249       19951212
     HR 960558           B1     20020430    HR 1996-558            19961125
     RO 119782           B1     20050330    RO 1996-2223           19961125
     EP 780390           A1     19970625    EP 1996-119134         19961129
     EP 780390           B1     20020731
          R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL,
             PT, SE
     AT 221531           T      20020815    AT 1996-119134         19961129
     PT 780390           T      20021129    PT 1996-119134         19961129
     ES 2179910          T3     20030201    ES 1996-119134         19961129
     US 5849752          A      19981215    US 1996-760543         19961205
     AU 9674216          A      19970619    AU 1996-74216          19961206
     AU 708006           B2     19990729
     TW 411340           B      20001111    TW 1996-85115048       19961206
     IN 185805           A1     20010505    IN 1996-DE2723         19961206
     CA 2192418          A1     19970613    CA 1996-2192418        19961209
     CA 2192418          C      20010612
     JP 09169757         A      19970630    JP 1996-344502         19961210
     JP 4104687          B2     20080618
     IL 119795           A      19981227    IL 1996-119795         19961210
     PL 184885           B1     20030131    PL 1996-317415         19961210
     NO 9605298          A      19970613    NO 1996-5298           19961211
     ZA 9610405          A      19970623    ZA 1996-10405          19961211
     BR 9605968          A      19980818    BR 1996-5968           19961211
     RU 2162468          C2     20010127    RU 1996-123410         19961211
     CZ 288657           B6     20010815    CZ 1996-3646           19961211
     EE 3474             B1     20010815    EE 1996-201            19961211
     SK 282805           B6     20021203    SK 1996-1591           19961211
     HU 9603428          A2     19970828    HU 1996-3428           19961212
     HU 9603428          A3     19971028
     CN 1160052          A      19970924    CN 1996-123220         19961212
     CN 1061348          C      20010131
PRAI DE 1995-19546249    A      19951212
IT   192927-63-2P
     RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
```

(pharmaceuticals containing diazabicyclononyldihydrocholinecarboxylate)
RN 192927-63-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

● H_2O

=> d bib hitstr 1-11

L5 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1396859 CAPLUS
DN 149:556602
TI Process for the preparation of Moxifloxacin hydrochloride
IN Ludescher, Johannes; Pise, Abhinay Chandrakant; Holkar, Anil Ganpat; Metkar, Shashikant
PA Sandoz A.-G., Switz.
SO PCT Int. Appl., 36pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008138759	A1	20081120	WO 2008-EP55300	20080430
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

EP 1992626 A1 20081119 EP 2007-107963 20070510
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS
PRAI EP 2007-107963 A 20070510
OS CASREACT 149:556602
IT 192927-63-2P, Moxifloxacin hydrochloride monohydrate
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of Moxifloxacin hydrochloride)
RN 192927-63-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

● H_2O

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1391817 CAPLUS
DN 149:556601
TI Process for the preparation of Moxifloxacin hydrochloride
PA Sandoz A.-G., Switz.
SO Eur. Pat. Appl., 24pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1992626	A1	20081119	EP 2007-107963	20070510
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
WO 2008138759	A1	20081120	WO 2008-EP55300	20080430
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,				

FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2007-107963 A 20070510

IT 192927-63-2P, Moxifloxacin hydrochloride monohydrate
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of Moxifloxacin hydrochloride)

RN 192927-63-2 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

● H_2O

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:619355 CAPLUS

DN 148:585741

TI Process for preparation of moxifloxacin hydrochloride and a novel polymorph thereof

IN Satyanarayana Reddy, Manne; Nagaraju, Chakilam; Thirumalai Rajan, Srinivasan; Kodanda Ramprasad, Achampeta; Satyanarayana, Revu

PA Msn Laboratories Limited, India

SO PCT Int. Appl., 42pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2008059521	A2	20080522	WO 2007-IN448	20070927
	WO 2008059521	A3	20080828		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	IN 2006CH02111	A	20081128	IN 2006-CH2111	20061114
	IN 2007CH01345	A	20090102	IN 2007-CH1345	20070625
PRAI	IN 2006-CH2111	A	20061114		
	IN 2007-CH1345	A	20070625		

OS CASREACT 148:585741; MARPAT 148:585741

IT 192927-63-2P
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of moxifloxacin hydrochloride and a novel polymorph thereof)

RN 192927-63-2 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

● H_2O

L5 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:10586 CAPLUS

DN 148:106026

TI Preparation of crystalline hydrohalide of an organic amine

IN Wieser, Josef; Lengauer, Hannes; Klingler, Elfriede; Pichler, Arthur; Sturm, Hubert

PA Sandoz A.-G., Switz.

SO PCT Int. Appl., 77pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008000418	A2	20080103	WO 2007-EP5596	20070625
	WO 2008000418	A3	20080228		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2007264030	A1	20080103	AU 2007-264030	20070625
PRAI	EP 2006-116134	A	20060627		
	WO 2007-EP5596	W	20070625		

IT 1000153-05-8P 1000153-06-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystalline hydrohalide of an organic amine)
RN 1000153-05-8 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, compd. with nitromethane (1:1:?) (CA INDEX NAME)

CM 1

CRN 186826-86-8
CMF C21 H24 F N3 O4 . Cl H

Absolute stereochemistry. Rotation (-).



● HCl

CM 2

CRN 75-52-5

CMF C H3 N O2

RN 1000153-06-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, acetate (1:?) (CA INDEX NAME)

CM 1

CRN 186826-86-8
CMF C21 H24 F N3 O4 . C1 H

Absolute stereochemistry. Rotation (-).



● HCl

CM 2

CRN 64-19-7
CMF C2 H4 O2

L5 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:87277 CAPLUS
DN 146:169364
TI Preparation of crystalline forms of moxifloxacin hydrochloride
IN Reddy, Manne Satyanarayana; Nagaraju, Chakilam; Rajan, Srinivasan Thirumalai; Ramprasad, Achampeta Kodanda
PA MSN Laboratories Limited, India
SO PCT Int. Appl., 20pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007010555	A2	20070125	WO 2006-IN244	20060713
	WO 2007010555	A3	20070412		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	IN 2005CH00948	A	20070727	IN 2005-CH948	20050715
PRAI	IN 2005-CH948	A	20050715		

IT 192927-63-2P, Moxifloxacin hydrochloride monohydrate
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of crystalline forms of moxifloxacin hydrochloride)

RN 192927-63-2 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

● H_2O

L5 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:374092 CAPLUS

DN 144:495318

TI Manufacture of freeze-dried powder injection of moxifloxacin or its salt

IN Wu, Xianggen

PA Peop. Rep. China

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 3 pp.

CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1729978	A	20060208	CN 2005-10093595	20050830
PRAI CN 2005-10093595		20050830		

IT 887646-53-9
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manufacture of freeze-dried powder injection of moxifloxacin or its salt)
RN 887646-53-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 151096-09-2
CMF C21 H24 F N3 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 64-19-7
CMF C2 H4 O2

L5 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:374087 CAPLUS
DN 145:14680
TI Manufacture of freeze dried powder injection of moxifloxacin or its salt
IN Wu, Xianggen
PA Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 2 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1729977	A	20060208	CN 2005-10092828	20050822
PRAI	CN 2005-10092828		20050822		

IT 887646-53-9
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manufacture of freeze dried powder injection of moxifloxacin or its salt)

RN 887646-53-9 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 151096-09-2
CMF C21 H24 F N3 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 64-19-7
CMF C2 H4 O2

L5 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:523453 CAPLUS
DN 143:48135
TI Process for the preparation of polymorphic crystalline forms of the antibiotic moxifloxacin hydrochloride
IN Turchetta, Stefano; Massardo, Pietro; Aromatario, Valentina
PA Chemi S.p.A., Italy
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005054240	A1	20050616	WO 2004-EP52699	20041028

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1685130 A1 20060802 EP 2004-791330 20041028

EP 1685130 B1 20081210

R: DE, ES, FR, GB, IT

JP 2007511580 T 20070510 JP 2006-540424 20041028

US 20070072895 A1 20070329 US 2006-580173 20060522

PRAI IT 2003-MI2259 A 20031120

US 2003-532779P P 20031224

WO 2004-EP52699 W 20041028

IT 192927-63-2, Moxifloxacin hydrochloride monohydrate

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(process for the preparation of polymorphic crystalline forms of the antibiotic

moxifloxacin hydrochloride)

RN 192927-63-2 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

● H_2O

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:120916 CAPLUS

DN 142:219263

TI Process for preparation of Moxifloxacin hydrochloride monohydrate from Et 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylate via (4aS-cis)-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylic acid (O3,O4)-bis(acyloxy)borate.

IN Chava, Satyanarayana; Gorantla, Seeta Ramanjaneyulu; Vasireddy, Umamaheswara Rao; Dammalapati, Venkata Lakshmi Narasimharao
PA Matrix Laboratories Ltd., India

SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012285	A1	20050210	WO 2004-IN233	20040805
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IN 2003CH00638	A	20051230	IN 2003-CH638	20030805
	EP 1651630	A1	20060503	EP 2004-770681	20040805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 20060264635	A1	20061123	US 2006-567131	20060207
PRAI	IN 2003-CH638	A	20030805		
	IN 2003-CH639	A	20030805		
	WO 2004-IN233	W	20040805		

OS CASREACT 142:219263

IT 192927-63-2P, Moxifloxacin hydrochloride monohydrate
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of Moxifloxacin hydrochloride from Et cyclopropyldifluoromethoxyoxodihydroquinolinecarboxylate via cyclopropyldiazabicyclononylfluoromethoxyoxodihydroquinoline carboxylic acid bisacetyloxyborate)

RN 192927-63-2 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

● H_2O

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:343718 CAPLUS
DN 131:5195
TI Preparation of 8-methoxyquinolonecarboxylates
IN Gehring, Reinhold; Mohrs, Klaus; Heilmann, Werner; Diehl, Herbert
PA Bayer A.-G., Germany
SO Ger. Offen., 16 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19751948	A1	19990527	DE 1997-19751948	19971124
	CA 2311540	A1	19990603	CA 1998-2311540	19981112
	WO 9926940	A2	19990603	WO 1998-EP7237	19981112
	WO 9926940	A3	19990812		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9915619	A	19990615	AU 1999-15619	19981112
	AU 732977	B2	20010503		
	EP 1034173	A2	20000913	EP 1998-959874	19981112
	EP 1034173	B1	20050427		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9814894	A	20001003	BR 1998-14894	19981112
	NZ 504657	A	20010427	NZ 1998-504657	19981112
	EE 200000241	A	20010615	EE 2000-241	19981112
	EE 4281	B1	20040415		
	HU 2000004337	A2	20011028	HU 2000-4337	19981112

	JP 2001524477	T	20011204	JP 2000-522098	19981112
	TR 200001472	T2	20020621	TR 2000-1472	19981112
	RU 2219175	C2	20031220	RU 2000-116546	19981112
	CN 1151151	C	20040526	CN 1998-811444	19981112
	AT 294169	T	20050515	AT 1998-959874	19981112
	ES 2241185	T3	20051016	ES 1998-959874	19981112
	CZ 297212	B6	20061011	CZ 2000-1926	19981112
	PL 192461	B1	20061031	PL 1998-341088	19981112
	SK 285492	B6	20070201	SK 2000-748	19981112
	IN 189753	A1	20030419	IN 1998-DE3456	19981118
	ZA 9810669	A	19990526	ZA 1998-10669	19981123
	TW 513427	B	20021211	TW 1998-87119353	19981123
	BG 104467	A	20010831	BG 2000-104467	20000522
	BG 64532	B1	20050630		
	NO 2000002637	A	20000523	NO 2000-2637	20000523
	NO 315748	B1	20031020		
	HR 2000000332	A1	20010430	HR 2000-332	20000523
	HK 1034080	A1	20050311	HK 2001-104581	20010703
	IN 2002DE00548	A	20040228	IN 2002-DE548	20020513
	IN 194719	A1	20041127		
	CN 1418879	A	20030521	CN 2002-131962	20020904
	CN 1200938	C	20050511		
	US 20030208069	A1	20031106	US 2003-406129	20030403
	US 6897315	B2	20050524		
	HK 1056169	A1	20051223	HK 2003-108394	20031118
	US 20050209276	A1	20050922	US 2005-127811	20050511
	US 7115744	B2	20061003		
PRAI	DE 1997-19751948	A	19971124		
	WO 1998-EP7237	W	19981112		
	IN 1998-DE3456	A3	19981118		
	US 2000-554985	A1	20000523		
	US 2003-406129	A3	20030403		

OS CASREACT 131:5195; MARPAT 131:5195

IT 192927-63-2P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of 8-methoxyquinolonecarboxylates)

RN 192927-63-2 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

● H_2O

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:231504 CAPLUS
DN 130:257360
TI Medicament formulation with controlled release of moxifloxacin
IN Siefert, Hans-Martin; Bosche, Patrick; Stass, Heino; Kettelhoit, Stefan; Laich, Tobias
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9915172	A1	19990401	WO 1998-EP5842	19980915
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2304135	A1	19990401	CA 1998-2304135	19980915
	CA 2304135	C	20090106		
	AU 9893484	A	19990412	AU 1998-93484	19980915
	AU 731693	B2	20010405		
	EP 1017392	A1	20000712	EP 1998-946454	19980915
	EP 1017392	B1	20020717		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9812553	A	20000725	BR 1998-12553	19980915
	TR 200000752	T2	20000921	TR 2000-752	19980915
	NZ 503538	A	20010330	NZ 1998-503538	19980915
	HU 2000003840	A2	20010428	HU 2000-3840	19980915
	HU 2000003840	A3	20060628		

	JP 2001517625	T	20011009	JP 2000-512541	19980915
	AT 220547	T	20020815	AT 1998-946454	19980915
	PT 1017392	T	20021031	PT 1998-946454	19980915
	ES 2179533	T3	20030116	ES 1998-946454	19980915
	SK 283462	B6	20030805	SK 2000-403	19980915
	CZ 293062	B6	20040114	CZ 2000-1076	19980915
	CN 1178659	C	20041208	CN 1998-809560	19980915
	CN 1623533	A	20050608	CN 2004-10085643	19980915
	PL 192273	B1	20060929	PL 1998-339349	19980915
	CN 1895233	A	20070117	CN 2006-10101640	19980915
	IN 1998DE02830	A	20070223	IN 1998-DE2830	19980921
	ZA 9808718	A	19990401	ZA 1998-8718	19980923
	TW 523412	B	20030311	TW 1998-87115867	19980924
	NO 2000001375	A	20000316	NO 2000-1375	20000316
	US 6270799	B1	20010807	US 2000-508868	20000317
	BG 104256	A	20001229	BG 2000-104256	20000320
	BG 64745	B1	20060228		
	MX 2000002929	A	20010306	MX 2000-2929	20000324
	HK 1032010	A1	20050916	HK 2001-102741	20010618
PRAI	DE 1997-19742243	A	19970925		
	CN 2004-10085643	A3	19980915		
	WO 1998-EP5842	W	19980915		

IT 192927-63-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicament formulation with controlled release of moxifloxacin)

RN 192927-63-2 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

● H_2O

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:87277 CAPLUS
DN 146:169364
TI Preparation of crystalline forms of moxifloxacin hydrochloride
IN Reddy, Manne Satyanarayana; Nagaraju, Chakilam; Rajan, Srinivasan Thirumalai; Ramprasad, Achampeta Kodanda
PA MSN Laboratories Limited, India
SO PCT Int. Appl., 20pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007010555	A2	20070125	WO 2006-IN244	20060713
	WO 2007010555	A3	20070412		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	IN 2005CH00948	A	20070727	IN 2005-CH948	20050715
PRAI	IN 2005-CH948	A	20050715		

IT 186826-86-8P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystalline forms of moxifloxacin hydrochloride)
RN 186826-86-8 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IT 139693-52-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of crystalline forms of moxifloxacin hydrochloride)

RN 139693-52-0 CAPLUS

CN Boron, bis(acetato-κO)[1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-(oxo-κO)-3-quinolinecarboxylato-κO3]-, (T-4)- (CA INDEX NAME)



L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:120916 CAPLUS

DN 142:219263

TI Process for preparation of Moxifloxacin hydrochloride monohydrate from Et 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylate via (4aS-cis)-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylic acid (O3,O4)-bis(acyloxy)borate.

IN Chava, Satyanarayana; Gorantla, Seeta Ramanjaneyulu; Vasireddy, Umamaheswara Rao; Dammalapati, Venkata Lakshmi Narasimharao

PA Matrix Laboratories Ltd., India

SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012285	A1	20050210	WO 2004-IN233	20040805
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IN 2003CH00638	A	20051230	IN 2003-CH638	20030805
	EP 1651630	A1	20060503	EP 2004-770681	20040805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 20060264635	A1	20061123	US 2006-567131	20060207
PRAI	IN 2003-CH638	A	20030805		
	IN 2003-CH639	A	20030805		
	WO 2004-IN233	W	20040805		

OS CASREACT 142:219263

IT 186826-86-8P, Moxifloxacin hydrochloride
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of Moxifloxacin hydrochloride from Et cyclopropyldifluoromethoxyoxodihydroquinolinecarboxylate via cyclopropyldiazabicyclononylfluoromethoxyoxodihydroquinoline carboxylic acid bisacetyloxyborate)
RN 186826-86-8 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IT 139693-52-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of Moxifloxacin hydrochloride from Et cyclopropyldifluoromethoxyoxodihydroquinolinecarboxylate via cyclopropyldiazabicyclononylfluoromethoxyoxodihydroquinoline carboxylic acid bisacetyloxyborate)
RN 139693-52-0 CAPLUS
CN Boron, bis(acetato-κO)[1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-(oxo-κO)-3-quinolinecarboxylato-κO3]-, (T-4)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s l8
L11          22 L8

=> s l11 and l1
            110 L1
L12           2 L11 AND L1

=> s l11 and us5849752/pn
              1 US5849752/PN
L13           0 L11 AND US5849752/PN

=> d bib l11 1-22

L11  ANSWER 1 OF 22  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2008:590874  CAPLUS
DN   148:538248
TI   Preparation of oxazolidinones linked to quinolones or naphthyridinones as
     antibacterials.
IN   Hubschwerlen, Christian; Panchaud, Philippe; Specklin, Jean-Luc
PA   Actelion Pharmaceuticals Ltd., Switz.
SO   PCT Int. Appl., 54pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
PI   WO 2008056335        A1    20080515    WO 2007-IB54557        20071109
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
PRAI WO 2006-IB54189      A     20061110
OS   MARPAT 148:538248
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11  ANSWER 2 OF 22  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2008:244603  CAPLUS
DN   150:144270
TI   Synthesis of 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-
     (methylamino)-1-piperidinyl]-4-oxo-3-quinolinecarboxylic acid
     (balofloxacin)
AU   Zhao, Wen-jing; Zhang, Yu-bin; Wang, Xiao-mei; Luo, Yong-hui
CS   Institute of Pharmacy, Yangtze River Pharmaceutical Group, Taizhou,
     225321, Peop. Rep. China
SO   Jiangsu Huagong (2007), 35(5), 27-28, 52
     CODEN: JHIUAC; ISSN: 1002-1116
PB   Jiangsu Huagong Bianjibu
DT   Journal
LA   Chinese

L11  ANSWER 3 OF 22  CAPLUS  COPYRIGHT 2009 ACS on STN
```

AN 2007:87277 CAPLUS
DN 146:169364
TI Preparation of crystalline forms of moxifloxacin hydrochloride
IN Reddy, Manne Satyanarayana; Nagaraju, Chakilam; Rajan, Srinivasan Thirumalai; Ramprasad, Achampeta Kodanda
PA MSN Laboratories Limited, India
SO PCT Int. Appl., 20pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007010555	A2	20070125	WO 2006-IN244	20060713
	WO 2007010555	A3	20070412		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	IN 2005CH00948	A	20070727	IN 2005-CH948	20050715
PRAI	IN 2005-CH948	A	20050715		

L11 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:69105 CAPLUS
DN 147:277479
TI Synthesis of quinolone analogues: 7-[2-aminomethylaziridin-1-yl]-quinolones
AU Jiang, Jin; Liu, Jiu Yu; Guo, Hui Yuan
CS Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China
SO Chinese Chemical Letters (2006), 17(11), 1431-1434
CODEN: CCLEE7; ISSN: 1001-8417
PB Chinese Chemical Society
DT Journal
LA English
OS CASREACT 147:277479
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:911321 CAPLUS
DN 147:257623
TI Synthesis of balofloxacin
AU Zhu, Ren-fa; Wang, Xiao-shan
CS Department of Chemistry, University of Science and Technology of China, Hefei, 230026, Peop. Rep. China
SO Zhongguo Xinyao Zazhi (2005), 14(9), 1162-1164
CODEN: ZXZHA6; ISSN: 1003-3734
PB Zhongguo Xinyao Zazhi Youxian Gongsi
DT Journal
LA Chinese
OS CASREACT 147:257623

L11 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1342697 CAPLUS
DN 145:489146
TI Synthesis and antibacterial activities of 7-[(2S)-2-hydroxymethyl-4-amino-1-pyrrolidinyl]fluoroquinolone derivatives
AU Chen, Shengxi; Guo, Huiyuan
CS Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China
SO Zhongguo Yiyao Gongye Zazhi (2005), 36(3), 129-132
CODEN: ZYGZEA; ISSN: 1001-8255
PB Zhongguo Yiyao Gongye Zazhi Bianjibu
DT Journal
LA Chinese
OS CASREACT 145:489146

L11 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:576981 CAPLUS
DN 145:188588
TI Synthesis and in vitro antibacterial activity of 7-[(2s)-2-amino methyl-pyrrolidine-1-yl]-quinolone derivatives
AU Chen, Shengxi; Guo, Huiyuan
CS Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China
SO Zhongguo Kangshengsu Zazhi (2004), 29(7), 397-400, 422
CODEN: ZKZAEY; ISSN: 1001-8689
PB Zhongguo Kangshengsu Zazhishe
DT Journal
LA Chinese
OS CASREACT 145:188588

L11 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:570890 CAPLUS
DN 143:97344
TI A preparation of quinoline and [1,8]naphthyridine derivatives, useful as antibiotics
IN Hubschwerlen, Christian; Specklin, J. L.; Baeschlin, Daniel Kaspar; Sigwalt, Christine; Mueller, Stefan; Cappi, Michael
PA Morphochem A.-G., Germany
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005058888	A2	20050630	WO 2004-EP14500	20041220
WO 2005058888	A3	20050818		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1557416	A1	20050727	EP 2004-1506	20040123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

	AU 2004299278	A1	20050630	AU 2004-299278	20041220
	CA 2549675	A1	20050630	CA 2004-2549675	20041220
	EP 1709044	A2	20061011	EP 2004-804099	20041220
	EP 1709044	B1	20080716		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1898238	A	20070117	CN 2004-80038072	20041220
	BR 2004017193	A	20070306	BR 2004-17193	20041220
	JP 2007516263	T	20070621	JP 2006-544382	20041220
	AT 401326	T	20080815	AT 2004-804099	20041220
	ES 2310299	T3	20090101	ES 2004-804099	20041220
	IN 2006MN00693	A	20070323	IN 2006-MN693	20060613
	MX 2006006769	A	20061219	MX 2006-6769	20060615
	KR 2007067003	A	20070627	KR 2006-714403	20060718
	HK 1090647	A1	20080905	HK 2006-112470	20061113
	US 20080027040	A1	20080131	US 2007-583419	20070928
PRAI	US 2003-530822P	P	20031218		
	EP 2004-1506	A	20040123		
	WO 2004-EP14500	W	20041220		

OS CASREACT 143:97344; MARPAT 143:97344
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:374694 CAPLUS
DN 144:253986
TI Synthesis of Gatifloxacin hydrochloride
AU Gu, Hai-ning; Jiang, Yong-xiang; Wang, Jin-song
CS Center of Analysis and Measurement, Zhejiang University, Hangzhou, 310028, Peop. Rep. China
SO Zhejiang Daxue Xuebao, Lixueban (2005), 32(1), 66-68, 74
CODEN: ZDXKF6; ISSN: 1008-9497
PB Zhejiang Daxue Chubanshe
DT Journal
LA Chinese
OS CASREACT 144:253986

L11 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:260050 CAPLUS
DN 142:336344
TI Preparation of quinolonecarboxylic acid derivatives as antibacterial agents
IN Asahina, Yoshikazu; Takei, Masaya
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026147	A1	20050324	WO 2004-JP13049	20040908
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2004272414	A1	20050324	AU 2004-272414	20040908
	CA 2536429	A1	20050324	CA 2004-2536429	20040908
	EP 1666477	A1	20060607	EP 2004-787732	20040908
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1849316	A	20061018	CN 2004-80026055	20040908
	CN 100410249	C	20080813		
	BR 2004013964	A	20061031	BR 2004-13964	20040908
	SG 144936	A1	20080828	SG 2008-5397	20040908
	NO 2006001050	A	20060404	NO 2006-1050	20060303
	IN 2006DN01310	A	20070803	IN 2006-DN1310	20060309
	MX 2006002817	A	20061110	MX 2006-2817	20060310
	KR 2006123096	A	20061201	KR 2006-705026	20060310
	US 20060281779	A1	20061214	US 2006-569062	20060330
PRAI	JP 2003-318897	A	20030910		
	WO 2004-JP13049	W	20040908		

OS MARPAT 142:336344
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:236678 CAPLUS
DN 144:71432
TI Synthesis of moxifloxacin
AU Liu, Mingliang; Wei, Yonggang; Sun, Lanying; Guo, Huiyuan
CS Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China
SO Zhongguo Yiyao Gongye Zazhi (2004), 35(3), 129-131
CODEN: ZYGZEA; ISSN: 1001-8255
PB Zhongguo Yiyao Gongye Zazhi Bianjibu
DT Journal
LA Chinese
OS CASREACT 144:71432

L11 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:120916 CAPLUS
DN 142:219263
TI Process for preparation of Moxifloxacin hydrochloride monohydrate from Et 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylate via (4aS-cis)-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylic acid (O3,O4)-bis(acyloxy)borate.
IN Chava, Satyanarayana; Gorantla, Seeta Ramanjaneyulu; Vasireddy, Umamaheswara Rao; Dammalapati, Venkata Lakshmi Narasimharao
PA Matrix Laboratories Ltd., India
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012285	A1	20050210	WO 2004-IN233	20040805
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IN 2003CH00638 A 20051230 IN 2003-CH638 20030805
EP 1651630 A1 20060503 EP 2004-770681 20040805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
US 20060264635 A1 20061123 US 2006-567131 20060207
PRAI IN 2003-CH638 A 20030805
IN 2003-CH639 A 20030805
WO 2004-IN233 W 20040805
OS CASREACT 142:219263
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:377789 CAPLUS
DN 142:134557
TI Separation of the main impurity demethylgatifloxacin from gatifloxacin and its synthesis and identification
AU Wang, Xiuzhen; Wang, Xintu; Wang, Erhua
CS Medicinal and Chemical Institute, China Pharmaceutical University, Nanjing, 210009, Peop. Rep. China
SO Zhongguo Yaoke Daxue Xuebao (2003), 34(3), 272-273
CODEN: ZHYXE9; ISSN: 1000-5048
PB Zhongguo Yaoke Daxue
DT Journal
LA Chinese
OS CASREACT 142:134557

L11 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:584068 CAPLUS
DN 135:312676
TI Preparation of boron complex with 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid and acetates
AU Guo, Yi; Yang, Jianhong; Fu, Yan
CS Hebei Provincial Institute for Drug Control, Shijiazhuang, 050011, Peop. Rep. China
SO Huaxue Shiji (2001), 23(3), 189
CODEN: HUSHDR; ISSN: 0258-3283
PB Huagongbu Huaxue Shiji Xinsizhan
DT Journal
LA Chinese
OS CASREACT 135:312676

L11 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:581868 CAPLUS
DN 135:166843
TI Sulfate salt of quinolonecarboxylic acid derivative and use thereof
IN Koike, Tomomi; Aiizawa, Yasuhiro
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001057017	A1	20010809	WO 2001-JP599	20010130

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
            HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
            LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
            SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
            ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    CA 2399516          A1   20010809    CA 2001-2399516         20010130
    AU 2001030525       A    20010814    AU 2001-30525           20010130
    EP 1253149          A1   20021030    EP 2001-902665          20010130
    EP 1253149          B1   20070912
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    AT 372997           T    20070915    AT 2001-902665          20010130
    TW 225057           B    20041211    TW 2001-90102019        20010201
    US 20030013882      A1   20030116    US 2002-182445          20020729
    US 6582609          B2   20030624
PRAI JP 2000-23609      A    20000201
    WO 2001-JP599       W    20010130
RE.CNT  36    THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11  ANSWER 16 OF 22  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   1999:27822  CAPLUS
DN   130:81423
TI   Preparation of cis-substituted fluoromethylpyrrolidine derivatives of
     1,4-dihydro-4-oxoquinoline-3-carboxylic acid as antibacterial agents
IN   Takemura, Makoto; Takahashi, Hisashi; Ohki, Hitoshi; Kimura, Kenichi;
     Miyauchi, Rie; Takeda, Toshiyuki
PA   Daiichi Pharmaceutical Co., Ltd., Japan
SO   PCT Int. Appl., 51 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ------------------  ----   --------    --------------------    --------
PI   WO 9858923          A1     19981230    WO 1998-JP2787          19980623
        W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
            DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
            KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,
            NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,
            UG, US, UZ, VN, YU, ZW
        RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
            CM, GA, GN, ML, MR, NE, SN, TD, TG
    AU 9880387          A      19990104    AU 1998-80387           19980623
    ZA 9805466          A      19990120    ZA 1998-5466            19980623
    EP 995744           A1     20000426    EP 1998-928627          19980623
    EP 995744           B1     20030212
        R:  BE, CH, DE, FR, GB, IT, LI, NL, SE
    TW 382625           B      20000221    TW 1998-87110150        19980624
    IN 1998MA01397      A      20090109    IN 1998-MA1397          19980624
    NO 9906390          A      20000224    NO 1999-6390            19991222
    US 20020072608      A1     20020613    US 1999-446696          19991223
    US 6656952          B2     20031202
PRAI JP 1997-166438     A      19970624
    JP 1998-54700       A      19980306
    WO 1998-JP2787      W      19980623
```

OS MARPAT 130:81423
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:713691 CAPLUS
DN 130:38341
TI Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents. [Erratum to document cited in CA129:290104]
AU Sakurai, Nobuhiro; Sano, Mitsuharu; Hirayama, Fumihiro; Kuroda, Tsuyoshi; Uemori, Satoru; Moriguchi, Akihiko; Yamamoto, Katsuhiro; Ikeda, Yoshifumi; Kawakita, Takeshi
CS Research Laboratories, Yoshitomi Pharmaceutical Industries Ltd., Fukuoka, 871-8550, Japan
SO Bioorganic & Medicinal Chemistry Letters (1998), 8(20), 2937
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English

L11 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:606891 CAPLUS
DN 129:290104
OREF 129:59123a,59126a
TI Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents
AU Sakurai, Nobuhiro; Sano, Mitsuharu; Hirayama, Fumihiro; Kuroda, Tsuyoshi; Uemori, Satoru; Moriguchi, Akihiko; Yamamoto, Katsuhiro; Ikeda, Yoshifumi; Kawakita, Takeshi
CS Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd., Fukuoka, 871-8550, Japan
SO Bioorganic & Medicinal Chemistry Letters (1998), 8(16), 2185-2190
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 129:290104
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1997:5821 CAPLUS
DN 126:47239
OREF 126:9317a,9320a
TI Purification of quinolonecarboxylic acid derivatives using nonpolar porous synthetic adsorbents
IN Matsumoto, Toyomi; Myashita, Kunio; Tamura, Shinya; Takahashi, Hiroshi; Oda, Kazuo; Matsukubo, Hiroshi
PA Kyorin Seiyaku Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08259540	A	19961008	JP 1995-90274	19950323
PRAI	JP 1995-90274		19950323		

OS MARPAT 126:47239

L11 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1997:5820 CAPLUS
DN 126:47238
OREF 126:9317a,9320a
TI Recovery of quinolonecarboxylic acid derivatives using nonpolar porous synthetic adsorbents
IN Matsumoto, Toyomi; Myashita, Kunio; Tamura, Shinya; Takahashi, Hiroshi; Oda, Kazuo; Matsukubo, Hiroshi
PA Kyorin Seiyaku Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 08259541	A	19961008	JP 1995-90275	19950323
PRAI JP 1995-90275		19950323		
OS MARPAT 126:47238				

L11 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1993:39150 CAPLUS
DN 118:39150
OREF 118:7142h,7143a
TI Preparation of lower trialkanoyloxyborons as quinolinecarboxylic acid materials
IN Ataka, Kikuo; Oku, Masayoshi
PA Ube Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04243882	A	19920831	JP 1991-19219	19910121
JP 2502198	B2	19960529		
PRAI JP 1991-19219		19910121		
OS CASREACT 118:39150; MARPAT 118:39150				

L11 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1992:152003 CAPLUS
DN 116:152003
OREF 116:25737a,25740a
TI (6,7-Substituted-8-alkoxy-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid O3,O4)bis(acyloxy-O)borates and the salts thereof, and methods for their manufacture
IN Takagi, Naomi; Fubasami, Hironobu; Matsukubo, Hiroshi
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 464823	A1	19920108	EP 1991-111139	19910704
EP 464823	B1	19990922		
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
JP 04069388	A	19920304	JP 1990-178765	19900706
JP 07078065	B	19950823		

	US 5157117	A	19921020	US 1991-724164	19910701
	ES 2137154	T3	19991216	ES 1991-111139	19910704
	CA 2046361	A1	19920107	CA 1991-2046361	19910705
	CA 2046361	C	19990720		
	HU 58747	A2	19920330	HU 1991-2279	19910705
	HU 215429	B	19990428		
	AU 9180263	A	19930128	AU 1991-80263	19910705
	AU 646055	B2	19940203		
	HU 222354	B1	20030628	HU 1998-2341	19910705
	CN 1059527	A	19920318	CN 1991-104666	19910706
	CN 1031795	C	19960515		
	FI 103794	B1	19990930	FI 1992-12	19920102
	AT 9200009	A	19931015	AT 1992-9	19920107
	AT 397656	B	19940627		
PRAI	JP 1990-178765	A	19900706		
	HU 1991-2279	A	19910705		
OS	CASREACT 116:152003; MARPAT 116:152003				

```
=> s 186826-86-8
L1            1 186826-86-8
                (186826-86-8/RN)

=> d

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   186826-86-8  REGISTRY
ED   Entered STN:  07 Mar 1997
CN   3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-
     [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride
     (1:1)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-
     (octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride,
     (4aS-cis)-
CN   3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-
     [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-,
     monohydrochloride (9CI)
OTHER NAMES:
CN   Actira
CN   Avalox
CN   Avelox
CN   BAY 12-8039
CN   Lapinix
CN   Moxifloxacin hydrochloride
CN   Octegra
FS   STEREOSEARCH
MF   C21 H24 F N3 O4 . Cl H
CI   COM
SR   CA
LC   STN Files:   ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CBNB, CHEMCATS,
       EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROUSDDR,
       PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
CRN  (151096-09-2)

Absolute stereochemistry.  Rotation (-).
```



● HCl

```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             108 REFERENCES IN FILE CA (1907 TO DATE)
```

110 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s 139693-52-0
L2             1 139693-52-0
                 (139693-52-0/RN)

=> d

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   139693-52-0  REGISTRY
ED   Entered STN:  20 Mar 1992
CN   Boron, bis(acetato-κO)[1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-
     methoxy-4-(oxo-κO)-3-quinolinecarboxylato-κO3]-, (T-4)-  (CA
     INDEX NAME)
OTHER CA INDEX NAMES:
CN   Boron, bis(acetato-O)(1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-
     oxo-3-quinolinecarboxylato-O3,O4)-, (T-4)-
MF   C18 H16 B F2 N O8
CI   CCS
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, USPAT2, USPATFULL
```



22 REFERENCES IN FILE CA (1907 TO DATE)
22 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     4.58       4.80

FILE 'CAPLUS' ENTERED AT 16:23:35 ON 25 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 25 Feb 2009 VOL 150 ISS 9
FILE LAST UPDATED: 24 Feb 2009 (20090224/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l1
L3   110 L1

=> s l2
L4   22 L2

=> s l3 and l4
L5   2 L3 AND L4

=> d bib abs 1-2

L5   ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN   2007:87277 CAPLUS
DN   146:169364
TI   Preparation of crystalline forms of moxifloxacin hydrochloride
IN   Reddy, Manne Satyanarayana; Nagaraju, Chakilam; Rajan, Srinivasan
     Thirumalai; Ramprasad, Achampeta Kodanda
PA   MSN Laboratories Limited, India
SO   PCT Int. Appl., 20pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007010555	A2	20070125	WO 2006-IN244	20060713
	WO 2007010555	A3	20070412		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA		
	IN 2005CH00948	A	20070727	IN 2005-CH948	20050715
PRAI	IN 2005-CH948	A	20050715		

AB   Novel crystalline forms of moxifloxacin hydrochloride and process for
preparation
     thereof. Moxifloxacin was prepared and converted to its HCl salt and a
     crystalline form of this compound was obtained.

L5   ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:120916 CAPLUS
DN 142:219263
TI Process for preparation of Moxifloxacin hydrochloride monohydrate from Et 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylate via (4aS-cis)-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylic acid (O3,O4)-bis(acyloxy)borate.
IN Chava, Satyanarayana; Gorantla, Seeta Ramanjaneyulu; Vasireddy, Umamaheswara Rao; Dammalapati, Venkata Lakshmi Narasimharao
PA Matrix Laboratories Ltd., India
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012285	A1	20050210	WO 2004-IN233	20040805
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IN 2003CH00638	A	20051230	IN 2003-CH638	20030805
	EP 1651630	A1	20060503	EP 2004-770681	20040805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 20060264635	A1	20061123	US 2006-567131	20060207
PRAI	IN 2003-CH638	A	20030805		
	IN 2003-CH639	A	20030805		
	WO 2004-IN233	W	20040805		

OS CASREACT 142:219263
AB A process for preparation of Moxifloxacin hydrochloride monohydrate comprises treatment of (4aS-cis)-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylic acid (O3,O4)-bis(acyloxy) borate with hydrochloric acid to give Moxifloxacin hydrochloride, and treatment of the latter with HCl in EtOH.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 144:71432 CASREACT
TI Synthesis of moxifloxacin
AU Liu, Mingliang; Wei, Yonggang; Sun, Lanying; Guo, Huiyuan
CS Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China
SO Zhongguo Yiyao Gongye Zazhi (2004), 35(3), 129-131
CODEN: ZYGZEA; ISSN: 1001-8255
PB Zhongguo Yiyao Gongye Zazhi Bianjibu
DT Journal
LA Chinese
CC 45-4 (Industrial Organic Chemicals, Leather, Fats, and Waxes)
Section cross-reference(s): 63
AB Moxifloxacin was synthesized from pyridine-2,3-dicarboxylic acid via dehydration, benzylamination, cyclization, reduction of pyridine ring and carbonyl groups, resolution, and debenzylation to afford (S,S)-octahydro-6H-pyrrolo[3,4-b]pyridine, which was condensed with the boric chelate of the quinolone intermediate and then hydrolysis. The overall yield of moxifloxacin was 43.3%.
ST moxifloxacin synthesis pyridine dicarboxylic acid
IT 89-00-9, 2,3-Pyridinedicarboxylic acid 139693-52-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(in synthesis of moxifloxacin)
IT 18184-75-3P 100872-65-9P 128740-13-6P 128740-14-7P 147459-51-6P 161594-54-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(in synthesis of moxifloxacin)
IT 100-46-9P, Benzylamine, preparation 151096-09-2P, Moxifloxacin
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of moxifloxacin)

RX(1) OF 18 A + B ===> C



A B C

RX(1) RCT A 89-00-9

STAGE(1)
SOL 108-24-7 Ac2O
CON 4.5 hours, reflux

STAGE(2)
RCT B 100-46-9
CON 30 minutes, room temperature

PRO C 100872-65-9

RX(2) OF 18 A + B ===> E...



A B E

YIELD 92%

RX(2) RCT A 89-00-9

STAGE(1)
SOL 108-24-7 Ac2O
CON 4.5 hours, reflux

STAGE(2)
RCT B 100-46-9
CON 30 minutes, room temperature

STAGE(3)
SOL 108-24-7 Ac2O
CON 3.5 hours, 125 deg C

PRO E 18184-75-3

RX(3) OF 18 ...E ===> F



E F

RX(3) RCT E 18184-75-3
RGT G 1333-74-0 H2
PRO F 128740-13-6
CAT 7440-05-3 Pd
SOL 109-99-9 THF
CON 5 hours, 85 deg C, 8 MPa

RX(4) OF 18 ...E ===> J...



E

(4)



J
YIELD 94%

RX(4) RCT E 18184-75-3

STAGE(1)
RGT G 1333-74-0 H2
CAT 7440-05-3 Pd
SOL 109-99-9 THF
CON 5 hours, 85 deg C, 8 MPa

STAGE(2)
RGT K 16853-85-3 LiAlH4
SOL 109-99-9 THF
CON 16 hours, reflux

STAGE(3)
RGT L 1310-73-2 NaOH
SOL 7732-18-5 Water, 109-99-9 THF
CON 1 hour, reflux

PRO J 128740-14-7

RX(5) OF 18 ...J ===> N...



J

(5)



N
YIELD 89%

RX(5) RCT J 128740-14-7

STAGE(1)
SOL 68-12-2 DMF
CON SUBSTAGE(1) 30 minutes, 80 deg C
SUBSTAGE(2) 1 hour, 80 deg C
SUBSTAGE(3) 1 hour, room temperature

STAGE(2)
RGT L 1310-73-2 NaOH

SOL 7732-18-5 Water
CON 1 hour, 90 - 100 deg C

PRO N 161594-54-3

RX(6) OF 18 ...N ===> P...



N

(6)



P
YIELD 90%

RX(6) RCT N 161594-54-3
RGT G 1333-74-0 H2
PRO P 147459-51-6
CAT 7440-05-3 Pd
SOL 67-56-1 MeOH
CON 16 hours, 90 deg C, 9 MPa

RX(7) OF 18 ...P + R ===> S



P



R

(7)



S
YIELD 81%

RX(7) RCT P 147459-51-6, R 139693-52-0

STAGE(1)
RGT T 121-44-8 Et3N
SOL 75-05-8 MeCN
CON 3 hours, reflux

STAGE(2)
RGT L 1310-73-2 NaOH
SOL 7732-18-5 Water
CON SUBSTAGE(1) 3 hours, 80 deg C
SUBSTAGE(2) 80 deg C -> room temperature

STAGE(3)
RGT U 64-19-7 AcOH
CON pH 7

PRO S 151096-09-2